[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vision-low\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vision-low":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,90,119,149,173],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":45,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":89},"100286660","stem-cell-ophthalmology-treatment-study-ii-100286660",false,"NCT03011541","Stem Cell Ophthalmology Treatment Study II","Bone Marrow Derived Stem Cell Ophthalmology Treatment Study II","SCOTS2","Inclusion Criteria:\n\n* Have objective, documented damage to the retina or optic nerve unlikely to improve OR\n* Have objective, documented damage to the retina or optic nerve that is progressive AND have less than or equal to 20\u002F30 best corrected central visual acuity in one or both eyes AND\u002FOR an abnormal visual field in one or both eyes.\n* Be at least 3 months post-surgical treatment intended to treat any ophthalmologic disease and stable.\n* If under current medical therapy ( pharmacologic treatment) for a retinal or optic nerve disease be considered stable on that treatment and unlikely to have visual function improvement ( for example, glaucoma with intraocular pressure stable on topical medications but visual field damage ).\n* Have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.\n* Be over the age of 18\n* Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure.\n* Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.\n\nExclusion Criteria:\n\n* Patients who are not capable of an adequate ophthalmologic examination or evaluation to document the pathology.\n* Patients who are not capable or not willing to undergo follow up eye exams with the principle investigator or their ophthalmologist or optometrist as outlined in the protocol.\n* Patients who are not capable of providing informed consent.\n* Patients who may be at significant risk to general health or to the eyes and visual function should they undergo the procedure.","ALL","18 Years",{"count":20,"type":21},500,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44],"Retinal Disease","Age-Related Macular Degeneration","Retinitis Pigmentosa","Stargardt Disease","Optic Neuropathy","Nonarteritic Ischemic Optic Neuropathy","Optic Atrophy","Optic Nerve Disease","Glaucoma","Leber Hereditary Optic Neuropathy","Blindness","Vision Loss Night","Vision Loss Partial","Vision, Low","Retinopathy","Maculopathy","Macular Degeneration","Retina Atrophy",[46,47,48,49,50,51,52,53,54,27,43,55,56,57,58,59,60,61,62,63,29,30,64,65,66,42,34,33,31,67,68,69,70,71,72,73,74,75,36,37,76,44],"Stem Cells","Bone Marrow Derived Stem Cells","BMSC","Mesenchymal Stem Cells","MSC","Eye Disease","Ophthalmology","Ophthalmic Disease","Retina","Age Related Macular Degeneration","Myopic Macular Degeneration","Geographic Atrophy","Dry Macular Degeneration","Wet Macular Degeneration","Retinal Atrophy","Retinal Dystrophy","Hereditary Retinal Dystrophy","Malattia Leventinese","Cone Dystrophy","Rod-Cone Dystrophy","Cone-Rod Dystrophy","Ischemic Optic Neuropathy","Optic Nerve Damage","Optic Nerve Compression","Compressive Optic Neuropathy","Devics Syndrome","Ushers Syndrome","Neuromyelitis Optica","Dominant Optic Atrophy","Kjers Optic Atrophy","Vision Loss","RECRUITING","2026-06-24",{"date":80,"type":81},"2026-06-29","ACTUAL",{"date":83,"type":81},"2016-01",{"date":85,"type":21},"2028-07-31",{"name":87,"class":88},"MD Stem Cells","INDUSTRY",4,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":97,"sex":17,"minAge":98,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":22,"phases":101,"briefSummary":102,"conditions":103,"keywords":105,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":118},"100618876","evaluating-stairway-designs-for-individuals-with-vision-impairment-100618876","NCT07337317","Evaluating Stairway Designs for Individuals With Vision Impairment","Frequency of Contrast Enhancement on Stairways","Inclusion Criteria:\n\n1. ≥ Contrast sensitivity log 1.6 or greater\n2. travels independently in the community, including stairways \\> two times\u002Fweek\n3. comfortable ascending and descending a stairway with rest time provided\n\n   Exclusion Criteria:\n4. severe rheumatologic and or orthopedic diseases (e.g., awaiting joint replacement, active inflammatory disease)\n5. lower-limb injuries and\u002For recent joint replacements (e.g., hip fracture, hip, or knee replacement within six months of study enrollment)",true,"65 Years",{"count":100,"type":21},65,[24],"The goal of this study is to learn if contrast frequency on step tread-edges influences foot clearance measures, a marker of fall risk, in older adults with and without visual impairments.\n\nThe main questions that aim to be answered are how foot clearance measures change across different frequencies of stair contrast, and how experiences and perceptions of different stair contrast frequencies are evaluated.\n\nResearchers will compare individuals with and without visual impairments to see if contrast frequency on step tread-edges changes.\n\nParticipants will attend one visit during which their vision will be measured, and they will be asked to ascend and descend laboratory stairs at different contrast frequencies.\n\nAn optional second visit will entail a focus group meeting to better understand how contrast affects mobility in their home and everyday life.",[40,104],"Mobility Limitation",[106,107],"older adults","impaired contrast sensivity","2026-04-27",{"date":110,"type":81},"2026-05-01",{"date":112,"type":81},"2026-01-22",{"date":114,"type":21},"2027-07",{"name":116,"class":117},"The University of Alabama in Huntsville","OTHER",1,{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":97,"sex":17,"minAge":126,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":131,"conditions":132,"keywords":134,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":118},"100485366","viewing-strategy-training-in-children-with-cerebral-visual-impairment-100485366","NCT05600140","Viewing Strategy Training in Children With (Cerebral) Visual Impairment","Viewing Strategy Training in Children With (Cerebral) Visual Impairment: From Spontaneous Eye Movements to a Structured Viewing Strategy","Inclusion criteria typically developing children with normal vision:\n\n* Age 5-12 years\n* linear distant visual acuity of 0.1 logMAR or better\n* Verbal IQ above 70\n* Absence of developmental disorders or psychiatric problems like ASS or AD(H)D\n\nInclusion criteria for children with ocular visual impairment:\n\n* Age 5-12 years\n* Children with linear distance visual acuity better \\\u003C=1.3logMAR and \\>0.1 logMAR\n* Intact central visual field (at least \\> 30 degrees)\n* Children with a verbal IQ above 70\n* Absence of developmental disorders or psychiatric problems like ASS or AD(H)D\n\nInclusion criteria for children with cerebral visual impairment:\n\n* Age 5-12 years\n* Linear distance visual acuity \\\u003C=0.3 logMAR\n* Having the diagnosis CVI (verified by ophthalmologists)\n* Children with a verbal IQ above 70\n* Absence of psychiatric problems like ASS or AD(H)D\n\nAdditional inclusion criterion for study 2 (evaluating training effectiveness): children with (cerebral) visual impairment should have an indication for viewing strategy training. Training should not be indicated if children have no problems performing academic tasks (i.e. when speed and accuracy of visual processing is within the normal range). The age range for study 2 is 5-9 years.\n\nExclusion criteria:\n\n* Children with VI: linear near visual acuity \\>1.0 logMAR\n* Children with visual field defect \\\u003C 30 degrees\n* Children with a verbal IQ below 70\n* Children who attended a form of vision training in the past two years\n* Children with psychiatric problems like ASS or AD(H)D\n* Auditory impairment or language impairments\n* Major life events during training","5 Years","12 Years",{"count":129,"type":21},60,[24],"Viewing strategies are strategies used to process visual Information. Many children with visual impairment seem to lack systematic viewing strategies. However, it is unknown how viewing strategies differ between children with normal vision and children with (cerebral) visual impairment. In addition, viewing strategy training is often adopted in clinical practice, but till date there is no scientific evidence about effectiveness of this approach.\n\nThe current project has two goals: (1) to measure viewing strategies used by children with normal vision, children with ocular visual impairment and children with CVI, and (2) to evaluate whether training viewing strategies results in more efficiënt visual Information processing.",[133,40],"Vision Disorders",[135,136,137,138,139],"viewing strategies","(cerebral) visual impairment","visual rehabilitation","reading strategies","visual search strategies","2026-01-05",{"date":142,"type":81},"2026-01-07",{"date":144,"type":81},"2024-10-25",{"date":146,"type":21},"2026-12",{"name":148,"class":117},"Royal Dutch Visio",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":97,"sex":17,"minAge":127,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":22,"phases":158,"briefSummary":159,"conditions":160,"keywords":161,"overallStatus":163,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":118},"100557562","validation-of-texture-changing-coatings-for-use-in-at-home-rapid-tests-100557562","NCT06539728","Validation of Texture Changing Coatings for Use in At-Home Rapid Tests","Validation of Texture-Changing Tactile Coatings for Potential Use in Accessible At-Home Care","Inclusion Criteria:\n\n* Visual Impairment: Participants should be blind or visually impaired for greater than 10 years, either congenitally or acquired.\n* Tactile Aid Usage: Participants must use tactile aids regularly.\n* Mathematical Knowledge: Participants should have a basic understanding of mathematical plots, equivalent to at least high school geometry.\n\nExclusion Criteria:\n\n* Limb Conditions: Participants with amputations or outer extremity conditions affecting hand use will be excluded.",{"count":157,"type":21},20,[24],"At-home testing is an important part of mitigating the spread of COVID-19, but these tests are not accessible to people with low vision or blindness. Instead of adapting to a technology originally built for sighted people, investigators propose a no-power version that reports test results through a texture change, which people can feel by touch. This platform could be used not only for COVID, but also for other diagnostics, and will promote the independence and privacy for people with low vision or blindness by removing the need for human assistance or an internet connection.",[40,37],[162],"Tactile Aid","NOT_YET_RECRUITING","2025-04-03",{"date":166,"type":81},"2025-04-06",{"date":168,"type":21},"2025-06",{"date":170,"type":21},"2025-08",{"name":172,"class":117},"University of Delaware",{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":97,"sex":17,"minAge":179,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":22,"phases":182,"briefSummary":183,"conditions":184,"keywords":185,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":118},"100534361","testing-tactile-aids-with-blind-subjects-100534361","NCT06237829","Testing Tactile Aids With Blind Subjects","Inclusion Criteria:\n\n* Visual Impairment: Participants should be blind or visually impaired for greater than 10 years, either congenitally or acquired.\n* Tactile Aid Usage: Participants must use tactile aids regularly.\n* Mathematical Knowledge: Participants should have a basic understanding of mathematical plots, equivalent to at least high school geometry.\n\nExclusion Criteria:\n\n\\- Limb Conditions: Participants with amputations or outer extremity conditions affecting hand use will be excluded.","16 Years",{"count":181,"type":21},100,[24],"The objective of this project is to create richer tactile aids by using materials chemistry to create tactile sensations in tactile aids, as an alternative to traditional physical bumps, lines, or textures. These materials are commonly used in household products, but have not yet been used to enrich tactile aids. Successful outcomes are primarily the accuracy with which low vision or blind subjects identify objects made from tactile coatings versus traditional tactile aids. Other outcomes include time to completion of the task, or the number of distinctive categories that participants can identify.",[40,37],[162],"2024-03-11",{"date":188,"type":81},"2024-03-13",{"date":190,"type":81},"2021-09-01",{"date":192,"type":21},"2027-12",{"name":172,"class":117}]